Analyst Price Targets — ADPT
Latest News for ADPT
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026. This sale represented 12.29% of Rubinstein's direct holdings at the time, reducing her directly held Common Stock to 408,160 shares.
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a…
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the company's stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $13.15, for a total value of $250,639.00. Following the completion of the sale, the chief operating officer owned 421,174
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction on Friday, April 10th. The shares were sold at an average price of $12.77, for a total transaction of $243,396.20. Following the completion of the sale, the chief operating officer directly owned 425,512 shares in
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADPT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.